Gimeracil

• Description :

  Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) [1][2].

• Product Name Alternative :

  Gimestat

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  Dihydropyrimidine Dehydrogenase (DPD) ; DNA/RNA Synthesis

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/gimeracil.html

• Concentration :

  10mM

• Purity :

  99.72

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C1C=C(O)C(Cl)=CN1

• Molecular Formula :

  C5H4ClNO2

• Molecular Weight :

  145.54

• Precautions :

  H302

• References & Citations :

  [1]Masaru Takagi, et al. Gimeracil sensitizes cells to radiation via inhibition of homologous recombination. Radiother Oncol. 2010 Aug;96 (2) :259-66.|[2]Koh-Ichi Sakata, et al. Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. Cancer Sci. 2011 Sep;102 (9) :1712-6.|[3]Masakazu Fukushima, et al. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep. 2010 Nov;24 (5) :1307-13.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [103766-25-2]